Sigma Planning’s Rein Therapeutics RNTX Stock Holding History
Bought
Maintained
Sold
Other funds holding RNTX
Sigma Planning's RNTX Position: Q3 2026 in Review
Sigma Planning increased its Rein Therapeutics (RNTX) stake by 1.1% in Q3 2026, buying an estimated $3.12K and bringing the position to 357,477 shares worth $287K. The position accounts for 0.01% of the portfolio, ranked #1082.
Sigma Planning first reported a position in RNTX in Q4 2023 and has held it in 12 quarters since. The position peaked at $752K in Q3 2024. 47 funds tracked by Wall St. Rank hold RNTX as of Q3 2026.
- Sigma Planning held 357,477 shares of Rein Therapeutics worth $287K as of Q3 2026.
- Sigma Planning bought 3,800 Rein Therapeutics shares in Q3 2026, an estimated $3.12K.
- Rein Therapeutics made up 0.01% of Sigma Planning's portfolio in Q3 2026, its #1082 holding.
- Sigma Planning first reported a position in Rein Therapeutics in Q4 2023 and has held it in 12 quarters since.
- Sigma Planning's Rein Therapeutics position peaked at $752K in Q3 2024.
- 47 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2026.
Based on Sigma Planning's 13F filing for Q3 2026, filed 23 Oct 2026.